secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001398733-26-000003
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA identifies deficiencies in Aquestive's Anaphylm NDA, precluding labeling talks
--------------------------------------------------------------------------------

- FDA letter notes deficiencies in Anaphylm NDA that preclude labeling and post-marketing discussions; review ongoing with PDUFA date Jan 31, 2026.
- Company working to understand and resolve deficiencies; delay in potential approval possible if concerns not resolved by PDUFA date.
- Unaudited cash and equivalents of ~$120M as of Dec 31, 2025; company believes it is sufficient for U.S. launch and global expansion.
- Global strategy advancing: expects to submit in Canada H1 2026, Europe H2 2026, and feedback from UK MHRA in Q1 2026.
- Anaphylm supported by 11 clinical studies with ~967 administrations; PK profile comparable to epinephrine auto-injectors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/0001398733-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aqst-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001398733-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer